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Abstract
Recent studies including genome-wide association studies have identified several putative low-
penetrance susceptibility loci for melanoma. We sought to determine their generalizability to 
genetic predisposition for multiple primary melanoma in the international population-based Genes, 
Environment, and Melanoma (GEM) Study. GEM is a case-control study of 1,206 incident cases 
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of multiple primary melanoma and 2,469 incident first primary melanoma participants as the 
control group. We investigated the odds of developing multiple primary melanoma for 47 single 
nucleotide polymorphisms (SNP) from 21 distinct genetic regions previously reported to be 
associated with melanoma. ORs and 95% CIs were determined using logistic regression models 
adjusted for baseline features (age, sex, age by sex interaction, and study center). We investigated 
univariable models and built multivariable models to assess independent effects of SNPs. Eleven 
SNPs in 6 gene neighborhoods (TERT/CLPTM1L, TYRP1, MTAP, TYR, NCOA6, and MX2) and a 
PARP1 haplotype were associated with multiple primary melanoma. In a multivariable model that 
included only the most statistically significant findings from univariable modeling and adjusted 
for pigmentary phenotype, back nevi, and baseline features, we found TERT/CLPTM1L rs401681 
(P = 0.004), TYRP1 rs2733832 (P = 0.006), MTAP rs1335510 (P = 0.0005), TYR rs10830253 (P = 
0.003), and MX2 rs45430 (P = 0.008) to be significantly associated with multiple primary 
melanoma while NCOA6 rs4911442 approached significance (P = 0.06). The GEM study provides 
additional evidence for the relevance of these genetic regions to melanoma risk and estimates the 
magnitude of the observed genetic effect on development of subsequent primary melanoma.
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Introduction
Clinically, melanoma is one of a small group of cancers where patients are at increased risk 
of potentially life-threatening subsequent primaries (1, 2) but the underlying genetic 
predispositions to multiple primaries are relatively unexplored. Recent genome wide 
association studies (GWAS) and candidate pathways studies have identified several low-
penetrant genetic variants associated with cutaneous melanoma (3, 4). The majority of these 
variants are in gene regions associated with fair pigmentation, such as TYRP1, TYR, HERC2/
OCA2, SLC45A2, and ASIP; nevi, such as PLA2G6, MTAP, and NID1; or both, such as IRF4 
(4–12). More recent GWAS have identified melanoma risk-associated variants in genes, 
including ATM, MX2, PARP1, ARNT, and CASP8, which may not be associated with 
phenotypic risk (8, 13). However, the risk associated with these low-penetrant genetic 
variants in relation to multiple primary melanomas has rarely been evaluated.
We studied these variants in the Genes, Environment and Melanoma (GEM) Study, a large, 
international population-based case-control study in which the ‘cases’ are patients with 
multiple primary melanoma (MPM) and the ‘controls’ are patients with single primary 
melanoma (SPM) (14, 15). Participants’ germline DNAs were genotyped for 47 
polymorphisms from 21 distinct genomic regions. We compared the odds of carrying the 
genotypes and haplotypes in MPM relative to SPM patients in univariable and multivariable 
analyses and assessed effect modification.
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The GEM Study is a population-based case-control study that enrolled 1,206 cases 
diagnosed with MPM (a second or higher order invasive or in situ primary melanoma) 
between 1998 and 2003 and 2,469 controls diagnosed with invasive SPM in 2000. In situ 
melanomas were eligible as MPM in order to take into account surveillance when the patient 
had a previous invasive melanoma. Patients were recruited from eight population-based 
cancer registries in the United States (New Jersey, North Carolina, California), Australia 
(New South Wales, Tasmania), Canada (Ontario, British Columbia), and Italy (Turin), and 
one hospital center in Michigan. GEM recruitment procedures and data collection have been 
described (14, 15). The Institutional Review Boards of all participating institutions approved 
the protocol; informed consent was obtained from each participant.
Demographic and melanoma risk factors, including hair and eye color, ability to tan, and 
number of back nevi, were collected from telephone interview and self-administered 
questionnaire. Using a glossy-colored guide to aid in differentiating between nevi and other 
skin lesions, subjects had the nevi on their backs counted by a family member or friend; and 
back nevi counts were categorized as 0–10 or >10 for this article. Back nevus counts were 
significantly correlated with whole-body nevus diagrams in GEM (data not shown). A 
phenotypic index variable was derived from additively combining: hair color (black or dark 
brown=0; light brown or blond=1; red=2), eye color (black or brown=0; green, grey, or 
hazel=1; blue=2), and ability to tan in response to sun exposure (deeply or moderately=0; 
occasionally or none=1). Those with index scores of 0 or 1 were defined as very low/low, 2 
as medium low, 3 as medium high, and 4 or 5 as high/very high risk.
Genotyping
DNA was collected from buccal swab kits. Single nucleotide polymorphisms (SNPs) were 
genotyped using the MassArray iPLEX platform (Sequenom Inc, San Diego, CA) with 
quality control measures as previously reported (16). Two SNPs of interest were not 
compatible with the Sequenom design, and proxy SNPs (r2 > 0.95) were chosen (1000 
Genomes, CEU population; Proxy SNP; Broad Institute).
Statistical Analyses
Logistic regression models were used to estimate the odds ratio (OR) and 95% confidence 
interval (95% CI) for each SNP assuming an additive model of inheritance of the variant 
allele. All models were adjusted for baseline features: age, sex, an age by sex interaction, 
and study center. For each locus with multiple associated SNPs, we applied stepwise logistic 
regression to determine the SNP with the strongest association from among the significantly 
associated SNPs, keeping baseline variables fixed.
For the genes with at least two SNPs genotyped, we determined their haplotype blocks using 
the Haploview software algorithm (17) based on the pair-wise linkage disequilibrium 
information of the GEM population in combination with the HapMap CEU population (18). 
Within each haplotype block, we inferred the haplotypes in terms of probabilities for each 
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individual from the SNP genotype input data using the PHASE algorithm, a Bayesian 
method in which the prior was chosen to approximate the coalescent process (19). For each 
haplotype block, the haplotype associations with MPM were assessed through haplotype 
trend regressions (HTR) (20). The HTR method effectively took into account the haplotype 
phase uncertainty and reduced bias by incorporating the inferred individual haplotype 
probabilities as the predictor variables in the regression models. Haplotypes with low 
estimated frequencies (< 0.01) were grouped together, reducing the number of haplotype 
categories and increasing the efficiency and power of haplotype analysis. Each haplotype or 
grouped rare haplotypes were then compared to the most common haplotypes in our study 
population.
Genotype and haplotype associations with phenotypic index were estimated using 
multinomial models and with back nevi using logistic regression models. In subsequent 
analyses, we limited the participants to those with no missing data for phenotypic index, 
back nevus counts, genotypes, and haplotypes of interest. Baseline models for genotypes and 
haplotypes were adjusted for baseline features; we then also adjusted the models for 
phenotypic index and back nevi; and finally also included all genotypes and haplotypes of 
interest in a multivariable model. Further, in exploratory stratified analyses, we assessed 
effect measure modification by phenotypic index and back nevus counts. The likelihood 
ratio test was used to test interactions, comparing models with main effects to models with 
main effects and interaction terms. All statistical tests were two-sided with P < 0.05 
considered statistically significant. All data were analyzed using R (http://www.r-
project.org/) or SAS 9.3 (Cary, NC) programs.
Results
The SPM and MPM patients’ age, sex, race, number of back nevi, phenotypic index, and 
tumors’ Breslow thicknesses are in Table S1. Twelve non-Caucasian patients were excluded 
from analyses. Forty-seven SNPs within 21 genetic loci previously reported to be 
association with melanoma were genotyped. SNP locations, minor allele frequencies, 
numbers of cases and controls genotyped, and literature references are in Table S2. Proxy 
SNPs rs6735656 and rs12278954 were used, respectively, for CASP8 rs10931936 and ATM 
rs1801516 identified by Barrett et al. (8).
Eleven SNPs in 6 gene neighborhoods (TERT/CLPTM1L, TYRP1, MTAP, TYR, NCOA6, and 
MX2) were significantly (P < 0.05) associated with MPM compared to SPM using additive 
models adjusted for baseline features (Table 1). The MTAP and TYR loci each had more than 
one significantly associated SNP. MTAP rs1335510 and TYR rs10830253 were brought 
forward for subsequent analyses because they each were the only SNP that remained in the 
stepwise logistic regression model for their locus.
Of the haplotypes examined (Tables 2 and S3), a PARP1 haplotype (rs3219090, rs2695238) 
was significantly (P = 0.03) associated with MPM, as were haplotypes in MTAP and TYR, 
when adjusting for baseline features. However the statistical significance of the MTAP and 
TYR haplotype associations with MPM were weaker than the respective single MTAP 
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rs1335510 and TYR rs10830253 SNP associations (Table S3). Thus, only the PARP1 
haplotype was selected for further analysis.
Several of the MPM-associated genotypes were associated with phenotypic index or back 
nevus counts (Table S4), indicating that these SNPs are correlated with these phenotypes 
and may increase risk of MPM via these phenotypes, which are known melanoma risk 
factors.
When limiting the dataset to patients with no missing data for genotypes, haplotype, or traits 
of interest (Table 3), the TERT/CLPTM1L, TYRP1, MTAP, TYR, NCOA6, and MX2 
genotypes, but not the PARP1 haplotype (P = 0.14), remained significantly associated with 
MPM after adjusting for baseline features. After additionally adjusting for phenotypic index 
and back nevi, the ORs did not appreciably change; although, the association with NCOA6 
rs4911442 became insignificant (P = 0.07). In a multivariable model further adjusting for 
genotypes and the PARP1 haplotype, the TERT/CLPTM1L, TYRP1, MTAP, TYR, and MX2 
genotypes remained significant, but the NCOA6 genotype (P = 0.06) and PARP1 haplotype 
(P = 0.22) did not; none of the ORs appreciably changed.
In an exploratory stratified analysis adjusted for baseline features, no evidence was found of 
effect modification by phenotypic index or back nevus counts on the association of 
genotypes with MPM (Table S5). However, there was evidence of effect modification by 
back nevi, but not phenotypic index, on the association between the PARP1 haplotype and 
MPM (P for interaction = 0.01). The PARP1 haplotype AG was negatively associated (P = 
0.02) with MPM when 0–10 back nevi were present, while both the AG (P = 0.03) and AC 
(P = 0.01) haplotypes were negatively associated with MPM when >10 back nevi were 
present.
Discussion
In the international GEM study, we found that SNPs in TERT/CLPTM1L, TYRP1, MTAP, 
TYR, NCOA6, and MX2 and a PARP1 haplotype were associated with the occurrence of 
MPM. TERT/CLPTM1L rs401681, TYRP1 rs1408799, MTAP rs1335510, TYR rs10830253, 
and MX2 rs45430 were associated with MPM independently of each other and of phenotypic 
index and back nevi. NCOA6 rs4911442 and the PARP1 haplotype were not significant in 
the multivariable model, possibly as a result of diminished statistical power as there was 
little change in the odds ratios. There was no evidence for effect modification of SNP 
associations with MPM by patient phenotype; however, back nevi did modify the 
association of the PARP1 haplotype with MPM.
The single SNP associations reported in GEM are in the same direction as those reported in 
the literature (Table S2). In a recent large meta-analysis, Chatzinasiou et al. found variants 
in 8 of the 21 low-penetrant loci examined in our study to have strong epidemiological 
credibility (Venice criteria overall grade, A) as associated with melanoma, although this 
study did not specify whether the associations were specific to MPM, SPM or both (21). 
Variants in each of these loci reached significance in our study except for PIGU rs910873 (P 
= 0.07), MYH7B rs1885120 (P = 0.11) and SLC45A2 rs16891982 (P = 0.14), the ORs of 
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which were in the same direction as previously reported. We are not aware of another group 
examining the PARP1 rs3219090, rs2695238 haplotype. Pena-Chilet et al. (22) found a 
similar trend towards protection from melanoma with a PARP1 haplotype containing the 
minor alleles of rs1136410 and rs3219090.
We know of only one other study addressing associations with MPM of common genetic 
variants in the loci discussed here. Helsing et al. (23) found no association of ASIP 
rs1015362 and rs4911414, TYR rs1126809, and TYRP1 rs1408799 with MPM in patients 
identified through the Norwegian Cancer Registry compared to melanoma-free blood 
donors. Although this design differs from GEM, we also found no association of ASIP 
rs4911414 and TYRP1 rs1408799 with MPM. We did not genotype ASIP rs1015362 and 
TYR rs1126809.
Strengths of our study include its large size, population-based case ascertainment, 
homogeneous questionnaire administration with respect to cases and controls, phenotypic 
trait adjustments, multivariable model, and examination of risk stratified by phenotypic 
traits. There may be a tendency for effect estimates of individual risk factors to be attenuated 
in our high baseline risk population (15). As evidence, several genotypes previously 
reported as associated with melanoma risk (PARP1 rs3219090, CASP8 rs13016963, TYRP1 
rs2733832, and PIGU rs910873) had borderline associations (0.10 < P ≥ 0.05) in the same 
direction as the literature in GEM. However, the GEM study estimates are more relevant for 
survivors and their risk of subsequent melanoma than studies investigating lower risk 
populations. A limitation is that GEM may not have had sufficient power to detect 
associations of SNPs with lower minor allele frequencies (e.g. SLC45A2 rs16891982, 
MAF=0.017).
Subsequent melanomas are a major problem for melanoma patients but few studies have 
explored their genetic predisposition. Our results provide evidence that several putative low-
penetrance susceptibility loci for melanoma are generalizable to risk of subsequent 
melanoma. Also, validation of genetic associations in the large international population-
based GEM study adds further credibility that these loci are melanoma risk-associated. 
Knowledge of genetic risk factors for subsequent melanoma could inform screening 
algorithms, future risk estimation modeling, and future prevention studies for melanoma 
survivors.
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